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The classical conversion site in precursors of regulatory peptides is a sequence of two basic amino acids. 
During recent years, however, a group of monobasic cleavage sites has emerged. In certain cell systems it 
has been shown that the monobasic cleavage mechanism is both a specific mechanism which only attacks 
a particular basic residue, and a distinct mechanism which can be separated from the dibasic cleaving mech- 
anism within the same cell. The vast majority of monobasic cleavages occur at single arginines although 
cleavage after a lysine residue has also been demonstrated. There is no ‘consensus equence’ of amino acids 
surrounding the single basic residue which is the apparent signal for proteolytic processing. However, in 
approximately one third of the cases, a proline residue is found either just before or just after the basic 
residue. On the basis of this ‘proline-directed arginyl cleavage’ it is discussed how the conformation of the 
peptide backbone might be important for this type of cleavage. Finally, it is suggested that tissue-specific 
expression of different processing enzymes, e.g. dibasic and monobasic specific forms, might explain the 
tissue-specific processing of precursors like the pro-opiomelanocortin and the CKK and somatostatin 
precursor. 
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1. INTRODUCTION 
Regulatory peptides are synthesized as part of 
relatively larger precursors which normally include 
the well-known signal peptide sequence. After the 
signal peptide has ensured that the primary transla- 
tion product is translocated into the cisternae of 
the endoplasmic reticulum, it is cleaved from the 
precursor. With the exception of a few hormones 
like growth hormone and prolactin [1,2], further 
proteolysis is required before the active regulatory 
peptide is generated. This secondary proteolytic 
event is generally performed by endopeptidases, 
although in a few cases, e.g. mellitin, a dipep- 
tidylpeptidase can be the activating enzyme [3]. 
The classical cleavage site is a sequence of two 
basic amino acids, as described in the pioneering 
work of Donald Steiner and Ronald Chance on 
proinsulin and Tager and Steiner on proglucagon 
(4-61. Such dibasic cleavage sites have been found 
in almost all precursors described since then. In 
higher eukaryotes the enzyme has as yet escaped 
final purification and characterization, mainly due 
to the fact that endoproteinases of similar 
specificity are found in large amounts in 
lysosomes. These are difficult to exclude during 
the preparation of secretory granules where the 
true processing enzymes are believed to be found in 
small amounts. In yeast, however, Thorner and co- 
workers [7,8] recently characterized the structural 
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gene for a similar processing enzyme with specifici- 
ty for pairs of basic residues. This elegant work 
was based on a strain of yeast which, due to a 
mutation in the enzyme, was unable to produce the 
active regulatory peptides a-factor and killer-toxin 
r71. 
Although the enzyme as such has not been 
isolated from mammals, we do know about its 
specificity in some detail. The cleavage seems to 
occur on the COOH-terminal side of the two basic 
residues, i.e. after the last one. The processing 
scheme, originally proposed by Steiner, consisted 
of such a tryptic-like cleavage followed by removal 
of the basic residues by a carboxypeptidase B-like 
enzyme [4,9]. The isolation and characterization of 
the carboxypeptidase B-like enzyme is likely to be 
imminent flO-121. All possible combinations of 
Lys and Arg are found in dibasic cleavage sites, 
However, the sequence Lys-Arg is most generally 
used [13]. It is not known if there are one or more 
different dibasic specific processing enzymes. In 
case there is only one enzyme responsible for all 
the dibasic cleavages known in precursors, this en- 
zyme can only recognize the two basic residue; as 
there is no other common sequence of amino acids 
on either side. However, pairs of basic residues do 
occur in precursors without being cleaved. Thus, it 
appears that either the two basic residues have to 
be presented to the enzyme in a particular confor- 
mation or there may exist several enzymes which in 
addition recognize some of the flanking, non-basic 
residues of the cleavage site. 
The fact that precursors are proteolytically 
cleaved after pairs of basic residues, as discussed 
above, is well established. Such sequences are in- 
evitably indicated when the cDNA deduced struc- 
tures of precursors are presented. However, within 
the last few years it has become clear that process- 
ing after single basic residues can also occur. As in- 
dicated in table 1, the list of precursors in which 
such a monobasic processing is found at present in- 
cludes precursors for hormones, growth factors, 
neuropeptides, an interleukin, frog skin peptides, 
and a yeast toxin. In the following, the monobasic 
cleavage mechanism is discussed in general and 
certain characteristics from specific cell systems 
are presented. Finally, it is discussed how the ex- 
istence of such a monobasic endopeptidase on the 
one hand makes it more difficult to predict which 
part of a cDNA deduced precursor will result in 
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Table 1 
Precursors for regulatory peptides that are cteaved by a 
monobasic specific endopeptidase (in most cases the 
major peptide product is stated) 
Hormones 
Pancreatic polypeptide 
Vasopressin 
Atria1 natriuretic polypeptide 
Somatostatin 
Relaxin 
Gastrin releasing peptide 
Growth factors 
Interleukin-3 
Insulin-like growth factor-I 
Insulin-like growth factor-II 
Neural growth factor 
Epidermal growth factor 
Neuropeptides 
Substance P 
Cholecystokinin 
FMRF-amide 
VIP 
Proenkephalin-A 
Proenkephalin-B 
Frog skin peptides 
Xenopsin 
PGLa 
Other peptides 
Yeast killer toxin 
Honey bee secapin 
Aplysia A and B peptides 
secretory peptides and, on the other, how it might 
help to explain tissue-specific processing of 
precursors. 
2. ‘PROLINE-DIRECTED ARGINYL 
CLEAVAGE’ - A SUBSET OF 
MONOBASIC PROCESSING INDICATING 
THE IMPORTANCE OF PEPTIDE 
CONFORMATION 
The only pattern which emerges when the amino 
acids surrounding monobasic cleavage sites are 
lined up is the frequent occurrence of proline 
residues either immediately before or after the 
arginine (fig.1). If the sequence is Pro-Arg, the 
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Fig. 1. Proline-directs arginyl cleavage and other 
monobasic cleavage sites in precursors of regulatory 
peptides. The relevant peptide product is indicated by a 
hatched bar and the name is written to the left followed 
by the number of a reference concerning either the 
precursor structure or the specific cleavage site. Prolines 
situated adjacent to target arginines are encircled. 
Vertical arrows point to the peptide bond which is 
suggested initially to be attacked by an endopeptidase 
(except in the case of dynorphin-B where the cleavage 
point suggested by Devi and Goldstein (291 is indicated 
by a long curved arrow). Short curved arrows indicate 
the following action of the carboxypeptidase B-like 
enzyme. Giycine residues, which subs~uently will serve 
as the nitrogen donor during the formation of an LY- 
carboxyamide group on the final bioactive peptide [40], 
have been put in separate hatched bars. 
scissile bond appears to be the one involving the 
carboxyl group of the Arg, but that involving the 
amino group when the sequence is Arg-Pro. In the 
case where the peptide fragment formed by the en- 
dopeptidergic cleavage ends in Pro-Arg, the car- 
boxypeptidase B-like enzyme cannot readily 
remove the arginine, and only around lo-15% of 
the molecules are trimmed in this way (un- 
published). 
The fact that prolines are found in the 
penultimate position to the single basic residue in 
about one third of the cases may be irn~~ant for 
the cleavage mechanism as proline will influence 
the three-dimensional orientation of the peptide 
backbone. The a-nitrogen atom in praline is part 
of the rigid pyrrolidine ring and no rotation of 
either the N-C bond in the ring or the peptide 
C-N bond is possible. Thus, a rigid kink or bend 
of the peptide chain is found at a proline residue. 
Proline can also introduce structural heterogeneity 
since unlike other peptide bonds, the X-Pro bond 
can be either of the stereoisomeric is or truns con- 
formation ]41]. It is possible that a particular 
X-Pro bond in a precursor will take up a certain 
isomeric form while the precursor is intact in the 
Golgi cisternae and the budding secretory granule. 
It should be noted in this context that the interior 
composition of the cell, in particular the secretory 
granule, is very complex and quite different from 
a test tube. In the first instance, the amount of 
water present is so low that there is barely enough 
for hydration of the proteins. It can be expected 
therefore that the proteins will be in a state rather 
similar to crystals [42]. In the second, if the precur- 
sor is first cleaved, for example by another en- 
doprotease, then it is likely that cis-trans 
isomerisation may occur since the energy barrier 
for isomerisation of the X-Pro bond is rather low 
[41]. Such conformational changes could very well 
be of importance in the processing scheme as it is 
known that enzymes can have a requirement for a 
particular conformation of the X-Pro bond 1433. 
In general, the special conformational constraint 
induced by proline residues will influence the rate 
at which proteolytic enzymes cleave peptides. 
Typically, prolines slow down the proteolysis. A 
classical example is the slow cleavage by trypsin 
between a basic residue and a proline. On the other 
hand, a proline residue can also make the peptide 
chain more susceptible to proteolysis; for example, 
3 
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it is known that the best substrates for thrombin 
have a proline situated just before the arginine 
1441. Thus, it is suggested that the prolines located 
around monobasic cleavage sites in peptide precur- 
sors are important in presenting the arginine in an 
optimal way to the processing enzyme. 
In a few of the examples listed in fig.1, it could 
be argued that the processing enzyme instead of 
being a distinct enzyme, directed by the following 
Arg-Pro sequence, is the well-known dibasic 
specific endopeptidase which in this case will not 
cleave between the Arg and the Pro but instead 
cleaves just before the Arg, which is still after a 
basic sequence. Generally, this argument has been 
used to explain the mechanism for processing of 
ACTH to wMSH and CLIP in the intermediary 
lobe of the pituitary. However, in the case of 
adrenorphin and dynorphin-A (l-8), there are no 
basic residues preceding the Arg-Pro sequence. It 
is suggested that these newly identified peptides in- 
dicate that a distinct type of enzyme is also in- 
volved in the biogenesis of more established hor- 
mones like a-MSH. This furthermore offers a sim- 
ple explanation for the tissue-specific processing of 
the pro-opiomelanocortin (see later). 
3. OTHER MONOBASIC CLEAVAGE SITES 
- A HETEROGENEOUS GROUP 
Apart from the role of a proline residue in di- 
recting cleavage at a monobasic site, there is no ob- 
vious ‘consensus equence’ which indicates that a 
particular basic residue is at a processing site. The 
only chemical feature which might be noted is that 
polar and charged amino acids, usually acidic 
ones, are dominating residues among those sur- 
rounding the monobasic cleavage site. Also, basic 
residues are frequently found three residues prior 
to the site (fig.1). 
The most likely processing mechanism is an in- 
itial cleavage on the carboxyl side of the arginine 
followed by the removal of the exposed basic 
residue by the carboxypeptidase B-like enzyme. 
Apparently, the basic residues are also removed 
from ‘non-biologically active’ spacer peptides, 
which has been shown with fragments of the CCK 
precursor [45]. In a few cases, for example 
neurophysin II, the arginine is not removed, 
although the primary structure of the peptide does 
not point to any obvious reason for this and the 
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secretory granules do have carboxypeptidase ac- 
tivity to remove basic residues from other 
fragments of the precursor, in this case from the 
vasopressin intermediate 1241. This could indicate 
that the single arginine is held in a particular steric 
configuration, in this case not determined by a 
neighbouring proline residue but probably by the 
structure of the rest of the neurophysin. 
Recently, an ~ino~ptidase with specificity for 
basic residues was reported in secretory granules 
from endocrine cells [46]. Thus, the possibility 
does exist that the endopeptidergic leavage initial- 
ly could happen on the NHz-terminal side of the 
arginine, whereafter this residue if needed can be 
removed by the aminopeptidase. In the case of 
dynorphin-B a preliminary report indicates that an 
endopeptidase in fact does cleave on the 
NHz-terminal side of the arginine [29]. 
The processing sites for neural growth factor 
(NGF) and epidermal growth factor (EGF) have 
been included in fig.1, ~though the biogenesis of 
l Pro-hormone 
3 
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Fig.2. Different kinetics of dibasic and monobasic 
processing in pancreatic polypeptide cells. The 
prohormone (O---O) which contains both a dibasic and 
a monobasic conversion site is initially labelled with 
radioactive amino acids daring a 30 min pulse period. 
The dibasic conversion of the precursor during the chase 
period follows a time course which is relatively rapid and 
similar to that of, e.g. proinsulin conversion. The 
monobasic cleavage happens later, apparently first after 
the precursor has been cleaved to an intermediate form 
(O--O) ([.52,53] and unpublished). 
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these peptides could very well be rather different 
from that of the neuropeptides for example. The 
processing enzymes for NGF and EGF are syn- 
thesized in parallel with the precursor in a molar 
ratio of 1: 1 [47,48], whereas the elusive processing 
enzymes for neuropeptides are believed to be 
found only in minute amounts as compared to 
their substrates, the peptide precursors. The pro- 
cessing enzyme for NGF, the so-called y-subunit of 
7S-NGF complex, has recently been cloned and 
shown to be a member of the glandular kallikrein 
multigene family which seems to comprise at least 
23 other non-allelic genes besides the NGF con- 
verting enzyme [49]. 
Processing after a single lysine residue has been 
quite well documented in only two cases. In the 
polyvalent precursor for FMRF-amide, which con- 
tains at least 19 copies of this peptide, it is assumed 
that monobasic cleavage takes place in at least 15 
places, followed by removal of the Lys and 
transformation of the exposed COOH-terming 
glycine to . the amide group 1391. The 
cholecystokinin precursor may also be cleaved 
after a single Lys, giving rise to cholecystokinin-22 
[45,50]. 
4. THE MONOBASIC CLEAVAGE CAN BE A 
SPECIFIC AND DISTINCT PROCESSING 
MECHANISM 
Several lines of evidence indicate that the 
monobasic cleavage mechanism can be distin- 
guished from the dibasic converting enzyme within 
the cell. Prohormone conversion through dibasic 
cleavage has been thoroughly studied in, for exam- 
ple, insulin-producing cells. Here it has been 
shown to occur just as the secretory granule buds 
off from the so-called ‘trans’ part of the Golgi 
complex, when the vesicles are still coated with 
clathrin (5 I]. During pulse-chase xperiments the 
radioactivity, which is incorporated into the pro- 
hormone form initially, is almost all converted into 
fragments after a 60-90 min chase period. In only 
a few cases are the kinetics of the monobasic con- 
version known. However, studies on the biogenesis 
of pancreatic icosapeptide from the pancreatic 
polypeptide precursor indicate that the monobasic 
cleavage occurs at quite a different time and place 
within the cell from the dibasic one. The initial 
cleavage of the precursor, at a dibasic site, has a 
time course very similar to that described for pro- 
insulin conversion [52], whereas the generation of 
the pancreatic icosapeptide from its intermediate 
form, through a monobasic cleavage, happens 
later (fig.2) [53]. In the same way, the generation 
of neurophysin II from its intermediary form is 
also a rather slow process [54]. Whether the late 
occurrence of monobasic cleavage is a general 
phenomenon remains to be seen. 
The dibasic specific processing enzyme cannot, 
in fact, cleave at single basic residues, which has 
been shown in naturally occurring cases of site- 
directed mutagenesis. If mutations happen at one 
of the basic residues in a cleavage site, in e.g. pro- 
insulin or pro~bumin, the normal cleavage process 
is prevented or greatly impaired 155,561. Further 
evidence for the notion that monobasic and dibasic 
processing can be distinct mechanisms is found in 
primary cultures of pancreatic polypeptide cells, in 
which the monobasic cleavage mechanism disap- 
pears after 24-48 h, whereas the dibasic process- 
ing mechanism functions perfectly well after 10 
days of culture [13,53]. This finding indicates that 
the monobasic-specific enzyme apparently needs 
some type of co-factor which is lost in time. The 
amidating enzyme also loses its activity due to the 
lack of a co-factor, conceivably ascorbate [57,58]. 
Generally, the monobasic processing enzyme 
must be highly specific as the precursors are not 
cleaved at the other single arginines found in them. 
This is true even when the possible miscleaved pep- 
tides are looked for specifically. Again, in the case 
of the precursor for pancreatic polypeptide, two of 
the other arginines are found in sequences imilar 
to the major monobasic cleavage site shown in 
fig.1. However, although peptides which are 
generated through miscleavage can be isolated and 
sequenced, the amount corresponds to less than 
1% of the major storage product, pancreatic 
icosapeptide (unpublished). 
5. PROBLEMS IN PREDICTING 
POSTTRANSLATIONAL MODIFICATIONS 
FROM cDNA DEDUCED PRECURSOR 
STRUCTURE 
Today almost all information concerning the 
structure of precursors is deduced from cDNA se- 
quences. Often, very little information, if any, is 
available concerning the peptide structure. Thus, 
5 
Volume 200, number 1 FEBS LETTERS 
one is forced to guess which posttranslational 
modifications will occur and thereby which pep- 
tides will be the products. There are some quite 
reliable methods of predicting the cleavage site be- 
tween the signal peptide and the propeptide [59]. 
However, as yet there is no way to identify which 
pairs of basic residues are conversion sites. Such 
pairs are therefore usually all pointed out as 
putative cleavage sites when precursor structures 
are published. In the same way, all the putative 
glycosylation sites (Asn-X-Thr/Ser) are indicated, 
although we do not know if these will in fact be 
derivatized. This problem is obviously even greater 
when monobasic cleavage sites are considered, but 
usually they are not. Monobasic cleavage sites can 
only be identified on the basis of firm peptide 
chemistry support. 
Some of the difficulties in predicting post- 
translational events are shown in fig.3. Had no 
peptide chemistry information been available when 
the complete structure for the pancreatic polypep- 
tide precursor was deduced from the cDNA struc- 
ture, a glycosylation site and a dibasic cleavage site 
would have been pointed out. However, neither of 
these is normally used (fig.3a) and, furthermore, 
the monobasic processing site, which in fact is 
used, would not have been noticed [14]. Recently, 
the introns in that gene have been located at both 
the monobasic and dibasic sites which in fact are 
used for proteolytic processing [60]. PGLB is an ac- 
tual example of how a dibasic site was initially 
guessed to be the processing site in a precursor 
which was deduced from a cDNA sequence [61]. 
When the peptide was eventually isolated and se- 
quenced, it turned out that the conversion took 
place at a monobasic site three residues further 
down the precursor (fig.1) [36]. 
Occasionally, some indirect evidence may in- 
dicate that an unnoticed monobasic site is used for 
conversion. The precursor for xenopsin is such an 
example (fig.3b). When the cDNA deduced precur- 
sor for this peptide was first published, a pair of 
basic residues was indicated as the major endopep- 
tidergic cleavage site [62]. However, no known 
processing enzyme is able to produce the final 
xenopsin molecule from the suggested in- 
termediary form. If instead the precursor is 
cleaved at a monobasic site three amino acids 
downstream, an attack by dipeptidylpeptidase IV, 
as shown by Kreil and co-workers [3] for pro- 
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Fig.3. Problems in predicting posttranslational 
modifications from cDNA deduced precursor structures. 
(a) The precursor for pancreatic polypeptide - two easily 
recognized processing sites are not used, a glycosylation, 
CHO, site, NAT (Asn-Ala-Thr), and a dibasic cleavage 
site RR (Arg-Arg); whereas a non-obvious monobasic 
cleavage site, PR (Pro-Arg), is used [14]. (b) The 
precursor for the frogskin peptide, xenopsin - the boxed 
sequence, KR, is the dibasic processing site initially 
suggested [62]. The vertical arrow points to a monobasic 
cleavage site which instead would result in an 
intermediary form, which can readily be turned into the 
final peptide product through the action of the 
dipeptidylpeptidase IV [3]. (c) The glucagon-like 
peptide-I, GLP-I, part of the mammalian precursor for 
glucagon - the boxed sequence, KR, is the dibasic 
conversion site initially suggested [63]. The arrow points 
to a monobasic cleavage site which instead would give 
rise to a glucagon-like peptide which has been preserved 
during evolution. The long line in the anglerfish 
structure indicates that these amino acids are not coded 
for in the gene [64]. The structure of the catfish peptide 
[65] and the Torpedo marmorata peptide (Conlon et al., 
unpublished) derived through peptide chemistry work 
are shown below the cDNA deduced precursor 
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mellitin, will easily activate the intermediary form 
(fig.3c). 
It is important which processing sites are in- 
dicated in a cDNA deduced precursor, since this 
almost always determines which peptides will be 
synthesized by pharmaceutical firms and eventual- 
ly tested for biological activity by physiologists. 
For obvious reasons, pairs of basic residues attract 
most attention. However, as pointed out this might 
be misleading. The precursor for glucagon is an ex- 
ample of a precursor which has been the template 
for the design of several peptides. It has generally 
been assumed that all the dibasic cleavage sites 
would be used to give rise to two glucagon-like 
peptides, GLP-I and GLP-II, in addition to some 
uninteresting fragments and of course glucagon 
itself [63]. In fact, it is a truncated form of GLP-I 
which has been preserved uring evolution [64,65]. 
This peptide, starting with the histidine residue 
which is important for glucagon-like activity, can 
be cleaved from the mammalian precursor by a 
monobasic specific cleaving enzyme (fig.3c). Thus, 
it could be argued that the truncated peptide is the 
true GLP-I. 
6. TISSUE-SPECIFIC EXPRESSION OF 
MONOBASIC SPECIFIC CONVERTING 
ENZYMES CAN EXPLAIN 
TISSUE-SPECIFIC PROCESSING OF 
CERTAIN PRECURSORS 
It is well known that the same primary transla- 
tion product can be processed differently in dif- 
ferent tissues. The most recognized example is the 
pro-opiomelanocortin which is processed to 
ACTH in the anterior lobe of the pituitary and to 
MSH in the intermediary lobe. The current most 
appealing explanation of this phenomenon is that 
proteolytic enzymes with different substrate 
specificity may exist and that they are expressed in 
a tissue-specific manner. This is already known to 
be the case for the acetylating enzyme of secretory 
granules which is found only in MSH cells [66]. 
Tissue-specific expression of monobasic specific 
converting enzymes could explain the selective pro- 
cessing of some precursors in different tissues. 
In fig.1 it is suggested that the cleavage of 
ACTH which gives rise to a-MSH and CLIP is per- 
formed by a proline-directed processing enzyme 
rather than the dibasic specific type of enzyme as 
generally believed. The selective xpression of such 
a conformation-dependent enzyme in only the 
melanocytes in the intermediary lobe of the 
pituitary could explain the occurrence of MSH on- 
ly in these cells. Recently, a converting enzyme 
with specificity for pairs of basic residues has been 
isolated from the pituitary. This enzyme cleaved all 
Lys-Arg sequences in pro-opiomelanocortin except 
the one at the MSH-CLIP junction, indicating that 
the structure at this site is different from normal 
dibasic sites [67] (this can be due either to the 
preceding Gly-Lys sequence or to the following 
Arg-Pro). 
The somatostatin precursor gives rise mainly to 
somatostatin-14 in for example the pancreas, but 
somatostatin-28 in the stomach [68,69]. In this 
case a tissue-specific expression of a dibasic- and a 
monobasic-specific processing enzyme can easily 
explain the different peptide patterns (fig.4). 
The proteolytic processing of the CCK precursor 
is mainly performed at monobasic sites (fig. 1). The 
only exception is the combined cleavage and 
amidation site just after CCK-8 [30] (fig.4). Cer- 
tain differences in the proteolysis of the CCK 
precursor have been described in different tissues 
[70]. In the guinea pig a very clear-cut separation 
of dibasic and monobasic processing is found. In 
the brain, the dominating CCK form is amidated 
CCK-8, which reflects both dibasic and monobasic 
processing, whereas in the small intestine the 
dominating CCK form is a large amidated form in- 
dicating that monobasic cleavages do not occur to 
any major extent (Hilsted, Rehfeld and Schwartz, 
unpublished). 
As the structure of many precursors has now 
been revealed, the concept of the cellular process- 
ing mechanism has changed somewhat. At present, 
the generalisation must be that cleavage of precur- 
sors occurs mainly at basic residues, more often at 
pairs but also at single basic residues. The distinc- 
tion between monobasic and dibasic cleavage 
mechanisms can be very clear in certain cells. It is 
possible, however, that families of converting en- 
zymes will be isolated, like the kallikrein family 
which already includes a monobasic specific con- 
verting enzyme [49]. Whether the monobasic and 
dibasic specific enzymes are related proteins re- 
mains to be seen. The frequent occurrence of pro- 
line residues, especially around monobasic 
cleavage sites, seems to indicate that besides the 
7 
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Fig.4 Tissue-special processing of precursors for 
regulatory peptides. (a) Pro-opiomelanocortin is 
processed toACTH, in the anterior lobe of the pituitary, 
but is further processed to cu-MSH in the intermediary 
lobe. In the text it is discussed how tissue-specific 
expression of an ACTH-cleaving enzyme, maybe a 
proline-dir~ting arginyl cleaving one, can explain this 
phenomenon. (b) The somatostatin precursor is 
processed mainly to somatostatin-14 in the 
hypothalamus, but to somatostatin-28 in the intestine. 
(c) The cholecystokinin precursor in the guinea pig brain 
is processed mainly to cholecystokinin-8, but to a large 
amidated form of chol~ystokinin in the small intestine 
of that animal (Hilsted et al., unpublished). In the latter 
two cases tissue-specific expression of dibasic specific 
(closed arrows) and monobasic specific (open arrows) 
processing enzymes can explain the occurrence of 
different peptides from the same precursor in different 
tissues. This scheme is a simplification since there is 
some processing to somatostatin-14 and to smaller forms 
of CCK in the tissues where the larger forms of these 
peptides are the dominating forms. 
amino acid sequence also the three-dimensional 
structure of the precursor is important for the pro- 
cessing mechanism. 
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